Table 1 Demographic and clinical characteristics of the cohort.
Characteristics | Classification | Total cohort, n = 144 |
|---|---|---|
Sex | Female, % (n) | 36.8 (53) |
Male, % (n) | 63.2 (91) | |
Age | At onset, years, mean (SD, R) | 59.9 (11.5; 25.8–81.5) |
At time of MME† use, years, mean (SD, R) | 62.1 (11.1; 29.6–82.8) | |
Disease duration | At time of MME† use, months, mean (SD, R) | 37.3 (49.7; 3.0–513.0) |
Disease progression | Mean (SD, R) | 0.7 (0.6; 0.0–2.8) |
ALS-FRS-R score (max. 48) | At time of survey, mean (SD, R) | 27.2 (9.8, 1.0–40.0) |
Presence of muscle stiffness | Total, yes, % (n) | 83.7 (113) |
In lower extremities, % (n) | 73.5 (97) | |
In upper extremities, % (n) | 69.6 (94) | |
Severity of muscle stiffness‡ | Mean (SD, R) | 3.7 (2.7, 0–9) |
In lower extremities, mean (SD, R) | 4.0 (3.2; 0–10) | |
In upper extremities, mean (SD, R) | 3.4 (3.1; 0–10) | |
Presence of muscle weakness | Yes, % (n) | 97.1 (133) |
In lower extremities, % (n) | 94.1 (127) | |
In upper extremities, % (n) | 91.8 (123) | |
Severity of muscle weakness‡ | Total, mean (SD, R) | 4.6 (2.3; 0–10) |
In lower extremities, mean (SD, R) | 4.8 (2.8; 0–10) | |
In upper extremities, mean (SD, R) | 4.3 (2.8; 0–10) |
